Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer.

Snyder, LB; Neklesa, TK; Chen, X; Dong, H; Ferraro, C; Gordon, DA; Macaluso, J; Pizzano, J; Wang, J; Willard, RR; Vitale, N; Peck, R; Moore, MD; Crews, CM; Houston, J; Crew, AP; Taylor, I

CANCER RESEARCH, 2021; 81 (13):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索